{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:47:43Z","timestamp":1792176463487,"version":"4.4.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Scripps Center for Health Equity","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To assess bias in and consent before drug testing during prenatal care and birth in a hospital system with a risk-factor\u2013based drug testing policy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>This retrospective cohort study included all patients who delivered in a regional hospital system from January 1, 2020, to June 1, 2022. Chart abstraction identified whether urine drug testing was performed and age, race, marital status, insurance status, ZIP code, gestational age, body mass index (BMI), and delivery mode. Propensity score matching through a pregnancy risk model was used to assess the association of race, insurance status, marital status, and median income with likelihood of testing. Data were analyzed with logistic regression. Charts of 200 randomly selected patients were also evaluated for documentation of consent, testing indication, test result, and child welfare reports.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Among 20,084 patients, 1,251 (6.2%) were tested, of whom 142 (11.3%) tested positive. White patients had a higher rate of positive test results (16.6%) compared with patients of other racial groups (overall rate 11.3%). None of the patients had consent documented. The most common indication for testing was limited prenatal care (48.7%). Fewer than a third of tests (28.5%) were obtained for a medical indication. The majority (67.9%) of positive results were reported to child welfare services.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Risk-factor\u2013based toxicology policies disproportionately target Black, low-income, single, publicly insured, and uninsured patients. Patients are typically not consented; testing is infrequently obtained for medical indications; and reports to child welfare services based on positive test results are common.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/og9.0000000000000044","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T22:09:34Z","timestamp":1732226974000},"page":"044","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating Bias and Racism in a Risk-Factor\u2013Based Drug Testing Policy in the Labor and Delivery Department"],"prefix":"10.1097","volume":"1","author":[{"given":"Arienne","family":"Malekmadani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Starikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishka","family":"Terplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12]]},"reference":[{"key":"R1-20241122","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1097\/AOG.0000000000002235","article-title":"Opioid use and opioid use disorder in pregnancy. Committee Opinion No. 711. American College of Obstetricians and Gynecologists","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R2-20241122","first-page":"163","article-title":"Challenges in perinatal drug testing","volume":"140","author":"Kurtz","year":"2022","journal-title":"Obstet Gynecol"},{"key":"R3-20241122","doi-asserted-by":"crossref","first-page":"e230441","DOI":"10.1001\/jamahealthforum.2023.0441","article-title":"Association of race with urine toxicology testing among pregnant patients during labor and delivery","volume":"4","author":"Jarlenski","year":"2023","journal-title":"JAMA Health Forum"},{"key":"R4-20241122","doi-asserted-by":"crossref","first-page":"e1379","DOI":"10.1542\/peds.2008-3525","article-title":"Infant race affects application of clinical guidelines when screening for drugs of abuse in newborns","volume":"125","author":"Ellsworth","year":"2010","journal-title":"Pediatrics"},{"key":"R5-20241122","doi-asserted-by":"crossref","first-page":"100733","DOI":"10.1016\/j.ajogmf.2022.100733","article-title":"Urine drug screening on labor and delivery","volume":"4","author":"Chin","year":"2022","journal-title":"Am J Obstet Gynecol MFM"},{"key":"R6-20241122","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s10995-021-03258-5","article-title":"Racial and ethnic differences in urine drug screening on labor and delivery","volume":"26","author":"Winchester","year":"2022","journal-title":"Matern Child Health J"},{"key":"R8-20241122","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/10408363.2020.1774493","article-title":"What the lab can and cannot do: clinical interpretation of drug testing results","volume":"57","author":"Kapur","year":"2020","journal-title":"Crit Rev Clin Lab Sci"},{"key":"R9-20241122","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/0897190015579611","article-title":"What can a urine drug screening immunoassay really tell us?","volume":"29","author":"Nelson","year":"2016","journal-title":"J Pharm Pract"},{"key":"R10-20241122","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.mayocp.2016.12.007","article-title":"Clinical interpretation of urine drug tests: what clinicians need to know about urine drug screens","volume":"92","author":"Moeller","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"R11-20241122","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0376-8716(93)90001-7","article-title":"Punishing pregnant drug users: enhancing the flight from care","volume":"31","author":"Poland","year":"1993","journal-title":"Drug Alcohol Depend"},{"key":"R12-20241122","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/AOG.0000000000001781","article-title":"Neonatal abstinence syndrome and ethical approaches to the identification of pregnant women who use drugs","volume":"129","author":"Terplan","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R13-20241122","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10995-010-0594-7","article-title":"Complex calculations: how drug use during pregnancy becomes a barrier to prenatal care","volume":"15","author":"Roberts","year":"2011","journal-title":"Matern Child Health J"},{"key":"R14-20241122","doi-asserted-by":"crossref","first-page":"412.e1","DOI":"10.1016\/j.ajog.2008.10.055","article-title":"Drug use and limited prenatal care: an examination of responsible barriers","volume":"200","author":"Schempf","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"R16-20241122","doi-asserted-by":"crossref","first-page":"105423","DOI":"10.1016\/j.chiabu.2021.105423","article-title":"Addressing the overrepresentation of Black children in Ontario's child welfare system: insights from child welfare workers and community service providers","volume":"123","author":"Antwi-Boasiako","year":"2022","journal-title":"Child Abuse Negl"},{"key":"R17-20241122","doi-asserted-by":"crossref","first-page":"B5","DOI":"10.1016\/j.ajog.2019.03.022","article-title":"Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine","volume":"221","author":"Ecker","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"R18-20241122","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/ADM.0000000000000323","article-title":"Appropriate use of drug testing in clinical addiction medicine","volume":"11","author":"Jarvis","year":"2017","journal-title":"J Addict Med"},{"key":"R20-20241122","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/09622802221133556","article-title":"An overview of propensity score matching methods for clustered data","volume":"32","author":"Langworthy","year":"2023","journal-title":"Stat Methods Med Res"},{"key":"R21-20241122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"key":"R22-20241122","doi-asserted-by":"crossref","first-page":"e20164070","DOI":"10.1542\/peds.2016-4070","article-title":"A public health response to opioid use in pregnancy","volume":"139","author":"Patrick","year":"2017","journal-title":"Pediatrics"},{"key":"R23-20241122","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/0091450918790790","article-title":"Drug use during pregnancy policies in the United States from 1970 to 2016","volume":"45","author":"Thomas","year":"2018","journal-title":"Contemp Drug Probl"},{"key":"R25-20241122","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1542\/hpeds.2019-0106","article-title":"Improving the child welfare system to respond to the needs of substance-exposed infants","volume":"9","author":"Patrick","year":"2019","journal-title":"Hosp Pediatr"},{"key":"R26-20241122","doi-asserted-by":"crossref","first-page":"100963","DOI":"10.1016\/j.ajogmf.2023.100963","article-title":"Assessing the clinical utility of toxicology testing in the peripartum period","volume":"5","author":"Siegel","year":"2023","journal-title":"Am J Obstet Gynecol MFM"},{"key":"R27-20241122","doi-asserted-by":"crossref","first-page":"101206","DOI":"10.1016\/j.ajogmf.2023.101206","article-title":"Reconsidering the use of urine drug testing in reproductive settings","volume":"5","author":"Martinez","year":"2023","journal-title":"Am J Obstet Gynecol MFM"}],"container-title":["O&amp;G Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/og9.0000000000000044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T11:01:52Z","timestamp":1732273312000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/og9.0000000000000044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/og9.0000000000000044","relation":{},"ISSN":["2994-9726"],"issn-type":[{"value":"2994-9726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"2024-07-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}